Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3-5 chronic kidney disease: a prospective observational study.
Aged
Biomarkers
/ blood
Blood Urea Nitrogen
Disease Progression
Female
Glomerular Filtration Rate
Humans
Japan
/ epidemiology
Kidney Failure, Chronic
/ blood
Male
Osmolar Concentration
Outcome Assessment, Health Care
Predictive Value of Tests
Prospective Studies
Risk Assessment
/ methods
Severity of Illness Index
Blood urea nitrogen
Chronic kidney disease
Renal outcome
Serum osmolality
Uremic toxicity
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
02 04 2019
02 04 2019
Historique:
received:
24
08
2018
accepted:
21
03
2019
entrez:
4
4
2019
pubmed:
4
4
2019
medline:
10
5
2020
Statut:
epublish
Résumé
Blood urea nitrogen (BUN) is one of the substances that affects the calculated serum osmolality (cSosm). A previous study demonstrated that BUN and cSosm were independently associated with the development of chronic kidney disease (CKD) in patients with preserved kidney function. In advanced CKD stages, there is a concomitant increase in cSosm and BUN levels. However, it remains unclear whether BUN or cSosm levels are related to renal outcomes in patients with moderate to severe kidney dysfunction. The aim of this study was to clarify whether the BUN or cSosm level is associated with kidney disease progression in patients with advanced CKD. In this prospective study, we enrolled 459 patients with CKD (stages 3-5). The composite renal endpoint was end-stage renal disease (ESRD) or death, and ESRD alone was added as an alternative outcome. A Cox proportional hazards model was utilized to determine the risk factors for a poor renal outcome. We adjusted for covariates including estimated glomerular filtration rate (eGFR). The cSosm (mOsm/kg) was calculated using the following formula: (2 × sodium) + (BUN/2.8) + (glucose/18). During a median follow-up of 25.8 months, the renal endpoint was observed in 210 patients. Multivariable Cox analysis determined the hazard ratio (HR) [95% confidence interval (CI)] for the composite renal outcome in the second, third, and fourth BUN quartiles were 1.36 (0.72-2.58), 1.87 (0.95-3.66), and 2.66 (1.23-5.76) (P for trend < 0.01), respectively compared with the first BUN quartile. Conversely, by multivariable Cox analysis, the HRs (95% CIs) for poor outcomes in the second, third, and fourth cSosm quartiles, compared with the first cSosm quartile, were 1.13 (0.69-1.87), 0.95 (0.58-1.55), and 1.26 (0.78-2.03), respectively (P for trend = 0.39). In addition, with regard to the renal outcome of ESRD alone, higher BUN quartiles had a significantly increased risk for the outcome, but cSosm levels were not associated with the outcome. Higher BUN levels, but not cSosm levels, were associated with adverse renal outcomes independent of the eGFR, suggesting that BUN may be a useful marker for predicting kidney disease progression.
Sections du résumé
BACKGROUND
Blood urea nitrogen (BUN) is one of the substances that affects the calculated serum osmolality (cSosm). A previous study demonstrated that BUN and cSosm were independently associated with the development of chronic kidney disease (CKD) in patients with preserved kidney function. In advanced CKD stages, there is a concomitant increase in cSosm and BUN levels. However, it remains unclear whether BUN or cSosm levels are related to renal outcomes in patients with moderate to severe kidney dysfunction. The aim of this study was to clarify whether the BUN or cSosm level is associated with kidney disease progression in patients with advanced CKD.
METHODS
In this prospective study, we enrolled 459 patients with CKD (stages 3-5). The composite renal endpoint was end-stage renal disease (ESRD) or death, and ESRD alone was added as an alternative outcome. A Cox proportional hazards model was utilized to determine the risk factors for a poor renal outcome. We adjusted for covariates including estimated glomerular filtration rate (eGFR). The cSosm (mOsm/kg) was calculated using the following formula: (2 × sodium) + (BUN/2.8) + (glucose/18).
RESULTS
During a median follow-up of 25.8 months, the renal endpoint was observed in 210 patients. Multivariable Cox analysis determined the hazard ratio (HR) [95% confidence interval (CI)] for the composite renal outcome in the second, third, and fourth BUN quartiles were 1.36 (0.72-2.58), 1.87 (0.95-3.66), and 2.66 (1.23-5.76) (P for trend < 0.01), respectively compared with the first BUN quartile. Conversely, by multivariable Cox analysis, the HRs (95% CIs) for poor outcomes in the second, third, and fourth cSosm quartiles, compared with the first cSosm quartile, were 1.13 (0.69-1.87), 0.95 (0.58-1.55), and 1.26 (0.78-2.03), respectively (P for trend = 0.39). In addition, with regard to the renal outcome of ESRD alone, higher BUN quartiles had a significantly increased risk for the outcome, but cSosm levels were not associated with the outcome.
CONCLUSIONS
Higher BUN levels, but not cSosm levels, were associated with adverse renal outcomes independent of the eGFR, suggesting that BUN may be a useful marker for predicting kidney disease progression.
Identifiants
pubmed: 30940101
doi: 10.1186/s12882-019-1306-1
pii: 10.1186/s12882-019-1306-1
pmc: PMC6444850
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
115Références
Eur J Clin Invest. 2005 Apr;35(4):245-50
pubmed: 15816993
Kidney Int. 2004 Nov;66(5):1988-93
pubmed: 15496170
Int J Nephrol Renovasc Dis. 2014 Jan 30;7:49-56
pubmed: 24501542
Arch Med Res. 2012 Aug;43(6):451-6
pubmed: 22885091
PLoS One. 2017 Aug 9;12(8):e0181373
pubmed: 28793319
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):235-245
pubmed: 29094800
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Kidney Int. 2015 Jun;87(6):1201-8
pubmed: 25671766
Clin Chem. 2011 Nov;57(11):1499-505
pubmed: 21768218
J Clin Invest. 2010 Jan;120(1):203-13
pubmed: 19955654
Kidney Int. 2018 Mar;93(3):741-752
pubmed: 29241622
J Am Soc Nephrol. 2013 Apr;24(5):853-61
pubmed: 23431074
J Am Soc Nephrol. 2009 Mar;20(3):545-53
pubmed: 19158351
Clin J Am Soc Nephrol. 2011 May;6(5):1066-72
pubmed: 21330484
Clin Chem. 1984 Oct;30(10):1703-5
pubmed: 6537784
Kidney Int. 2004 Oct;66(4):1606-12
pubmed: 15458457
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1444-58
pubmed: 25078422
Ann Intern Med. 1966 Dec;65(6):1287-99
pubmed: 5928490
Am J Cardiol. 2008 Jun 1;101(11):1643-7
pubmed: 18489944
Clin Sci (Lond). 2017 Jan 1;131(1):3-12
pubmed: 27872172
Nephrol Dial Transplant. 2018 Jan 1;33(1):4-12
pubmed: 28407121
Clin Exp Nephrol. 2017 Jun;21(3):446-456
pubmed: 27412450
Am J Kidney Dis. 2014 Nov;64(5):793-803
pubmed: 25037561
Sci Transl Med. 2013 Mar 6;5(175):175ra29
pubmed: 23467560
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001892
pubmed: 19588328
Circ J. 2017 Sep 25;81(10):1454-1462
pubmed: 28450669
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002181
pubmed: 17943769
Am J Kidney Dis. 2006 Nov;48(5):752-60
pubmed: 17059994
J Am Soc Nephrol. 2016 Jul;27(7):2164-76
pubmed: 26823552
J Lab Clin Med. 1999 Mar;133(3):302-8
pubmed: 10072262
Am J Physiol Renal Physiol. 2011 Sep;301(3):F476-85
pubmed: 21367923
Am J Physiol. 1990 Apr;258(4 Pt 2):F973-9
pubmed: 2184677
N Engl J Med. 1994 Mar 31;330(13):877-84
pubmed: 8114857
PLoS One. 2017 Jan 12;12(1):e0169137
pubmed: 28081152
Nephrol Dial Transplant. 2011 Mar;26(3):938-47
pubmed: 20884620
Atherosclerosis. 2015 Apr;239(2):393-400
pubmed: 25682038
J Clin Invest. 2016 Sep 1;126(9):3598-612
pubmed: 27525435
Clin Chem. 1996 Mar;42(3):482-3
pubmed: 8598126
Diabetologia. 2002 Jun;45(6):877-82
pubmed: 12107732